There are now over a dozen licensed disease modifying therapies (DMTs) for people with relapsing MS, and some emerging for early active progressive MS. But to help people at every stage of MS, we need to stop MS from progressing.
Currently, all available DMTs target the immune system. To truly stop MS getting worse, we also need treatments that protect nerves from damage and repair lost myelin.
Now, after years of planning, our ambition to speed up clinical trials for progressive MS is becoming a reality. With recruitment starting later this year, Octopus will provide a smarter way of testing potential MS drugs. This could deliver life-changing new treatments up to three times faster. Read on.